Site Map     Privacy & Terms

Letter from the CEO

Corporate Governance

    Management Team

    Board of Directors

Stock Information

SEC Filings

Corporate Presentations

Annual Reports

Investor Events



Letter from the CEO

The Wall Street Transcript's Interview with Christopher M. Cashman, CEO

Dear Investor,

   Thank you for visiting the investor relations section of the SANUWAVE, Inc. Website. We hope you find the site to be a valuable resource to answer your questions about our company.

   SANUWAVE is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE's portfolio of products and product candidates activate biologic signaling and angiogenic responses including revascularization and improved microcirculation, helping restore the body's normal healing processes and regeneration. SANUWAVE is applying its Pulsed Acoustic Cellular Expression (PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.

   We have already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through our legacy U.S. Class III PMA approved Ossatron® device and in the European community for the stimulation of bone and chronic tendonitis regeneration in the musculoskeletal environment. Our lead development product for the global wound care market, dermaPACE™, has received CE marking for use on acute and chronic defects of the skin and subcutaneous soft tissue, and in the U.S. the dermaPACE is currently under investigation for our first advanced indication, the treatment of diabetic foot ulcers, in an FDA approved Investigational Device Exception (IDE) clinical trial.

   We are now entirely focused on developing this technology to stimulate tissue healing in all wound healing conditions to include diabetic foot ulcers (DFU), decubitus ulcers (pressure sores), burns and other skin eruption conditions; orthopedic/spine applications such as fracture healing and fusion, creating improved bone density in osteoporosis and to eliminate chronic pain from trauma or arthritis; plastic/cosmetic applications such as massage therapy for cellulite, preconditioning for graft and transplant acceptance, skin tightening, scarring and other potential aesthetic uses; and potential developments in cardiac indications for removing plaque due to atherosclerosis and improving blood supply to the heart muscle.

   We believe we are developing a safe and advanced technology in the wound healing and tissue regeneration market with PACE. dermaPACE is non-invasive and does not require anesthesia, making it a cost-effective, time-efficient and painless approach to wound care. Physicians and nurses look for therapies that can accelerate the healing process and overcome the obstacles of patients' compromised conditions, and prefer therapies that are easy to administer and that are minimally disruptive to the patient's or the caregiver's daily routines.

   We have a track record of developing products by relying on our products that have been previously authorized for marketing by the FDA and by leveraging the lessons learned from those previous experiences as the cornerstone for further development and regulatory approvals.

   We are very encouraged by the support that the medical community has shown us, and we believe that we will offer the healthcare community and their patients a unique solution to demanding medical problems at a reasonable cost.

Christopher M. Cashman

President and Chief Executive Officer

Investor Relations

Barry Jenkins, CFO
Bernie Laurel, VP Sales & Marketing

Copyright © 2006-2010 SANUWAVE, Inc. All Rights Reserved. OssaTron, EvoTron, VersaTron, dermaPACE, OrthoTripsy and “Healing Today. Curing Tomorrow.” are all registered trademarks of SANUWAVE.